Mark McLoughlin Brings Four Decades of Healthcare Industry Experience to the Company’s Board State College, PA (13 August 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the appointment of Mark McLoughlin to the Company’s Board of Directors. Mark brings four decades of healthcare industry experience to theRead More
INDIGO Biosciences Announces Release of Assay Kit for Testing Multi-Drug Resistance
Testing Allows Researchers to Determine Possibility of Drug-Drug Interactions Before Clinical Trials State College, PA (19 June 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay to their portfolio. This kit expands INDIGO’sRead More
INDIGO Biosciences Announces Release of Predictive Liver Toxicity Assay Kit
By combining the advantages of upcyte hepatocytes with INDIGO’s industry-leading platform and science, the new hepatotoxicty assay kit helps researchers get the information they need to confidently advance their discovery processes.
INDIGO Biosciences Announces Release of Gene Expression Kit Utilizing upcyte® Hepatocytes
Portfolio Expansion Helps Researchers Move to the Next Stage of Discovery Faster State College, PA (December 5, 2018) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor research, announced the addition of a gene expression assay kit featuring upcyte® hepatocytes to their portfolio. This addition both complements INDIGO’s industry-leading nuclear receptor assays andRead More